Form 4: ARGAN Director Exercises Stock Options Under 10b5-1 Plan
Insider Transaction Report
ARGAN Inc. Director Cynthia Flanders exercised multiple stock options on January 13, 2026, acquiring 26,079 shares of common stock under a Rule 10b5-1 plan.
Summary
- Cynthia Flanders, a Director of ARGAN Inc. (AGX), exercised stock options on January 13, 2026.
- The transactions were conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
- She exercised options to purchase a total of 30,000 shares across four separate grants.
- Using a net settle method, she acquired a total of 26,079 shares of common stock.
- The exercise prices for these options ranged from $35.72 to $45.75 per share.
- Following these transactions, her direct beneficial ownership of common stock increased to 45,207 shares.
- Her remaining derivative securities (options) decreased to 1,500.
Sentiment
Score: 5
Explanation: Neutral. This is a routine disclosure of an insider exercising stock options under a pre-arranged plan, which is a standard compensation and investment activity. It does not inherently signal positive or negative company performance.
Positives
- Director Cynthia Flanders increased her direct beneficial ownership in ARGAN Inc. by 26,079 shares, demonstrating continued alignment with shareholder interests.
- The transactions were executed under a Rule 10b5-1(c) plan, indicating pre-planned and transparent insider trading activity.
Future Outlook
NA
Industry Context
This Form 4 filing reflects a routine insider transaction, specifically the exercise of stock options by a director. Such transactions are common and typically do not indicate broader industry trends or competitive shifts, but rather individual compensation and investment strategies.
Stakeholder Impact
- Shareholders: The increase in direct beneficial ownership by a director may be viewed positively as it aligns management's interests with shareholders.
- Employees: No direct impact on employees is indicated by this filing.
- Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 12/23/2019 | Award date for stock option to purchase 10,000 shares at $40.15. |
| 12/14/2020 | Award date for stock option to purchase 10,000 shares at $45.75. |
| 12/14/2021 | Award date for stock option to purchase 5,000 shares at $37.13. |
| 12/16/2022 | Award date for stock option to purchase 5,000 shares at $35.72. |
| 01/13/2026 | Date of stock option exercises. |
| 01/14/2026 | Signature date of the reporting person. |
| 12/23/2029 | Expiration date for stock option awarded on 12/23/2019. |
| 12/14/2030 | Expiration date for stock option awarded on 12/14/2020. |
| 12/14/2031 | Expiration date for stock option awarded on 12/14/2021. |
| 12/16/2032 | Expiration date for stock option awarded on 12/16/2022. |
Keywords
ARGAN Inc., AGX, Cynthia Flanders, Director, Stock Options, Insider Trading, Form 4, Equity, Beneficial Ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.